3 active not recruiting, 3 completed, 1 recruiting. 5 Phase 1, 2 Phase 2.
By phase and status
Follow RO7795081: new trials by email Literature Review of RO7795081 trials Research Report on RO7795081
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions
RO7795081 - Renal Impairment | Phase 1 | Recruiting | Hoffmann-La Roche | 60 | 2026-09-09 | 2026-10-09 |
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
RO7795081, Placebo - Healthy Volunteers, Overweight or Obesity | Phase 1 | Active not recruiting | Hoffmann-La Roche | 30 | 2026-03-30 | 2026-08-10 |
A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes
RO7795081, Semaglutide, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Active not recruiting | Hoffmann-La Roche | 330 | 2025-08-19 | 2026-10-01 |
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
RO7795081, Placebo - Obesity or Overweight | Phase 2 | Completed | Hoffmann-La Roche | 352 | 2025-07-29 | 2026-08-21 |
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants
RO7795081, Placebo, Rosuvastatin - Overweight, Obesity | Phase 1 | Active not recruiting | Hoffmann-La Roche | 40 | 2025-06-04 | 2026-09-09 |
A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081
RO7795081, Itraconazole, Gemfibrozil - Healthy Participants | Phase 1 | Completed | Hoffmann-La Roche | 36 | 2025-02-13 | 2026-09-28 |
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
CT-996, Placebo - Type 2 Diabetes, Overweight or Obesity | Phase 1 | Completed | Carmot Australia First Pty Ltd | 94 | 2023-05-09 | 2025-11-28 |
Conditions studied
Obesity (4) · Overweight (4) · Diabetes Mellitus, Type 2 (2) · Renal Insufficiency (1)
Sponsors
Hoffmann-La Roche (6) · Carmot Australia First Pty Ltd (1)
Countries
United States (3) · Netherlands (2) · Australia (1) · China (1) · Hungary (1) · Mexico (1) · Poland (1) · Spain (1)